What Is Teprotide? Definition and What Research Reports

Definition

Teprotide (also indexed in older literature as SQ 20,881) is a synthetic nonapeptide whose sequence was modelled on the bradykinin-potentiating peptides isolated from the venom of the Brazilian pit viper Bothrops jararaca. It is classed pharmacologically as an inhibitor of angiotensin-converting enzyme (ACE), the dipeptidyl carboxypeptidase also known as kininase II, which converts angiotensin I into the vasoconstrictor angiotensin II and which also degrades bradykinin. Because teprotide is a peptide rather than a small orally active molecule, it appears in the experimental record as a parenterally administered laboratory and investigational agent rather than as a marketed medicine, and it is usually described as the historical forerunner of the orally active ACE inhibitors that followed it, such as captopril.

Quick reference

Where the molecule comes from

The teprotide story begins with venom chemistry. Peptides found in Bothrops jararaca venom were observed to potentiate the actions of bradykinin, and structural work on that peptide family produced a synthetic nonapeptide that inhibited the same enzyme responsible for both angiotensin I conversion and bradykinin breakdown. That dual identity — one enzyme, two substrate pathways — is why teprotide turns up in papers on blood pressure regulation and in papers on kinin biology. It is also why the compound is frequently used as a definitional example in teaching material about peptide drug discovery: a naturally occurring peptide motif was characterised, synthesised, and then used as the starting point for non-peptide inhibitors.

How the term is used in peptide research

In the published literature, "teprotide" is most often encountered not as the subject of a study but as a reagent: an ACE inhibitor administered to animals or isolated preparations so that researchers could observe what happened when angiotensin II generation was interrupted. Papers comparing several different ways of interfering with the renin–angiotensin system have grouped converting-enzyme inhibition alongside renin inhibition and receptor antagonism (PMID 2412016). Reviews of blood ACE have continued to treat converting-enzyme inhibition as a central experimental manipulation, with later work examining conformational changes of blood ACE in chronic uremia (PMID 23166630).

Readers scanning older cardiovascular papers should therefore expect the term to appear in methods sections rather than titles. The three contexts in which it recurs are: (1) acute haemodynamic experiments in anaesthetised or pithed animals; (2) models of renal and cardiac disease in which angiotensin II is suspected of driving vasoconstriction; and (3) kinin-pathway studies, where inhibiting kininase II is used to probe bradykinin signalling.

What the Published Literature Reports

Cardiovascular and renal physiology models

Much of the relevant body of work is animal physiology. A 1988 study in the pithed rat examined interactions between angiotensin II and alpha-adrenoceptor agonists in mediating pressor responses, a preparation used because it removes central nervous and reflex contributions (PMID 2905911). Converting-enzyme inhibition has also been used to interrogate pressure-regulating mechanisms inside the brain, and one 1987 report examined the effect of inhibiting central angiotensin pressor mechanisms on blood pressure in spontaneously hypertensive rats (PMID 2437396).

On the renal side, a 1985 study measured systemic and renal haemodynamic changes during acute unilateral renal arterial stenosis, a classic setting in which angiotensin II generation rises (PMID 4061672). A 1986 review discussed the role of the kidney in congestive heart failure and the place of the renin–angiotensin system within that syndrome (PMID 3461687). Related work asked which vasoconstrictor systems dominate under mechanical load, with a 1988 study examining the vasoconstrictor role of vasopressin and angiotensin in experimental aortic stenosis in the rat (PMID 2455839). Vasoconstrictor mechanisms were likewise invoked in a 1987 surgical paper on the fundamental haemodynamic mechanism underlying gastric "stress ulceration" in cardiogenic shock (PMID 3592803).

Kinins and off-target enzymology

Because ACE and kininase II are the same enzyme, converting-enzyme inhibitors also feature in kinin research: a 1989 study examined ACE inhibitors and the expression of des-Arg9-bradykinin (kinin B1) receptors in vivo (PMID 2540986). Separately, work on the small-molecule successor compounds has looked beyond the renin–angiotensin system altogether; a 1989 paper reported that captopril inhibits ouabain-sensitive Na+/K+-ATPase (PMID 2547542). That finding concerns captopril rather than teprotide, and is included here only to illustrate that the class is not assumed in the literature to act through a single mechanism.

Teprotide and the oral inhibitors that followed

Glossary users often arrive at this term while reading about captopril or enalapril. The distinction commonly drawn is structural and practical: teprotide is a peptide of nine residues derived from a venom template, whereas the inhibitors that displaced it in clinical medicine are smaller synthetic molecules. Comparative pharmacology papers examining different ways of interfering with the renin–angiotensin system have treated these agents as tools with differing potency, route and duration characteristics (PMID 2412016). No dosing figures for teprotide are reproduced on this page, because the verified source set summarised here does not supply them.

Adverse Events: What Studies Report

The verified literature summarised here does not contain a teprotide-specific safety series. What it does contain is a 1986 review of adverse reactions with angiotensin-converting enzyme inhibitors as a drug class, which surveyed the reaction patterns reported for these agents (PMID 3023783). Because that review addressed the class rather than this specific nonapeptide, its findings cannot be transferred to teprotide without qualification, and researchers reading it should note the difference in molecule, route and era. Kinin-pathway effects are also relevant to any discussion of converting-enzyme inhibitor tolerability, and the 1989 in vivo study of kinin B1 receptor expression under ACE inhibition is part of that mechanistic background (PMID 2540986).

Limits of this entry

• The material above is descriptive: it records what published papers examined, not what any compound does in a person.
• Most of the cited work is animal physiology from the 1980s, and the study designs reflect the questions and methods of that period.
• Several cited papers concern ACE inhibition generally or captopril specifically rather than teprotide, and are labelled as such in the text.
• No quantities, schedules or administration details are given here, because the verified sources indexed for this entry do not supply them.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, and note that nothing here describes a protocol, product or course of action for an individual.

References

• Interactions between angiotensin II and alpha-adrenoceptor agonists mediating pressor responses in the pithed rat (British Journal of Pharmacology, 1988)
• Captopril inhibits ouabain-sensitive Na+/K+-ATPase (Clinical Physiology and Biochemistry, 1989)
• Role of the kidney in congestive heart failure (Acta Medica Scandinavica Supplementum, 1986)
• Systemic and renal hemodynamic changes during acute unilateral renal arterial stenosis (American Journal of Physiology, 1985)
• The fundamental hemodynamic mechanism underlying gastric "stress ulceration" in cardiogenic shock (Annals of Surgery, 1987)
• Angiotensin converting enzyme inhibitors and expression of des-Arg9-BK (kinin B1) receptors in vivo (European Journal of Pharmacology, 1989)
• Comparison of different drug interference with the renin-angiotensin system (Journal of Cardiovascular Pharmacology, 1985)
• Vasoconstrictor role of vasopressin and angiotensin in experimental aortic stenosis in the rat (Journal of Cardiovascular Pharmacology, 1988)
• Effect of inhibition of central angiotensin pressor mechanisms on blood pressure in spontaneously hypertensive rats (Journal of Cardiovascular Pharmacology, 1987)
• Adverse reactions with angiotensin converting enzyme (ACE) inhibitors (Medical Toxicology, 1986)
• Conformational changes of blood ACE in chronic uremia (PLoS One, 2012)